Cansino Biologics Stock Book Value Per Share
| CASBF Stock | USD 3.90 0.00 0.00% |
CanSino Biologics fundamentals help investors to digest information that contributes to CanSino Biologics' financial success or failures. It also enables traders to predict the movement of CanSino Pink Sheet. The fundamental analysis module provides a way to measure CanSino Biologics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to CanSino Biologics pink sheet.
CanSino |
CanSino Biologics Company Book Value Per Share Analysis
CanSino Biologics' Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
More About Book Value Per Share | All Equity Analysis
Book Value per Share | = | Common EquityAverage Shares |
Current CanSino Biologics Book Value Per Share | 29.22 X |
Most of CanSino Biologics' fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, CanSino Biologics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
| Competition |
In accordance with the recently published financial statements, the book value per share of CanSino Biologics is about 29.223 times. This is 1819.0% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The book value per share for all United States stocks is 98.49% higher than that of the company.
CanSino Book Value Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses CanSino Biologics' direct or indirect competition against its Book Value Per Share to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of CanSino Biologics could also be used in its relative valuation, which is a method of valuing CanSino Biologics by comparing valuation metrics of similar companies.CanSino Biologics is currently under evaluation in book value per share category among its peers.
CanSino Fundamentals
| Return On Equity | 0.0111 | |||
| Return On Asset | -0.0207 | |||
| Profit Margin | 0.06 % | |||
| Operating Margin | (0.19) % | |||
| Current Valuation | 3.58 B | |||
| Shares Outstanding | 114.78 M | |||
| Shares Owned By Insiders | 26.70 % | |||
| Shares Owned By Institutions | 38.17 % | |||
| Price To Earning | 19.25 X | |||
| Price To Book | 2.30 X | |||
| Price To Sales | 2.51 X | |||
| Revenue | 4.3 B | |||
| Gross Profit | 3 B | |||
| EBITDA | 2.05 B | |||
| Net Income | 1.91 B | |||
| Cash And Equivalents | 7 B | |||
| Cash Per Share | 28.36 X | |||
| Total Debt | 40 M | |||
| Debt To Equity | 0.26 % | |||
| Current Ratio | 2.99 X | |||
| Book Value Per Share | 29.22 X | |||
| Cash Flow From Operations | 2.05 B | |||
| Earnings Per Share | 0.59 X | |||
| Number Of Employees | 1.95 K | |||
| Beta | 0.61 | |||
| Market Capitalization | 3.15 B | |||
| Total Asset | 11.87 B | |||
| Z Score | 46.8 | |||
| Annual Yield | 0.01 % | |||
| Net Asset | 11.87 B | |||
| Last Dividend Paid | 0.8 |
About CanSino Biologics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze CanSino Biologics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CanSino Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CanSino Biologics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in CanSino Pink Sheet
CanSino Biologics financial ratios help investors to determine whether CanSino Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in CanSino with respect to the benefits of owning CanSino Biologics security.